Development of Health Risk Assessment Guidance; Public Forum, 82400-82402 [2010-32963]
Download as PDF
<![CDATA[
82400
Federal Register / Vol. 75, No. 250 / Thursday, December 30, 2010 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Stakeholders Meeting To Provide
Updates on NIOSH-Funded Research,
Certification and Standards, Educate
Participants on Resources To
Reinforce the Proper Use of NIOSHCertified Respirators, and Explore
Personal Protective Technology Use in
Industry Sectors
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of a public meeting.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH), Personal Protective
Technology (PPT) Program and National
Personal Protective Technology
Laboratory (NPPTL) will conduct a
stakeholders meeting to provide updates
on NIOSH-funded research, certification
and standards, educate participants on
resources to reinforce the proper use of
NIOSH-certified respirators, and explore
personal protective technology use in
industry sectors. In addition, conformity
assessment (certification and standards)
needs and gaps relative to the personal
protective technology will be discussed
at this meeting.
DATES: The public meeting will be held
8 a.m. to 5 p.m., March 29, 2011.
ADDRESSES: The public meeting will be
held at Hyatt Regency Pittsburgh
International Airport, 1111 Airport
Boulevard, Pittsburgh, PA 15231,
telephone 724–899–1234.
FOR FURTHER INFORMATION CONTACT: Ed
Fries, NPPTL, Office of the Director,
P.O. Box 18070, Pittsburgh, PA 15236,
telephone 412–386–6111, fax 412–386–
4951, E-mail npptlevents@cdc.gov.
SUPPLEMENTARY INFORMATION:
Status: The meeting will be open to
the public, limited only by the space
available. The meeting room
accommodates approximately 200
people. Preregistration is recommended.
This meeting will also be available
through remote access capabilities
(Microsoft Live Meeting), whereby
participants simultaneously listen and
view presentations over the internet.
This option will be available to
participants on a first-come, first-serve
basis and is limited to the first 100
participants. Preregistration for this
option is required.
Instructions: Registration and
additional Information is available on
jlentini on DSKJ8SOYB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:41 Dec 29, 2010
Jkt 223001
the NIOSH NPPTL Web site, https://
www.cdc.gov/niosh/npptl or by
contacting NIOSH NPPTL Office of the
Director, P.O. Box 18070, Pittsburgh, PA
15236, telephone 412–386–6111, fax
412–386–6617, E-mail
npptlevents@cdc.gov.
Background: While this meeting will
highlight the personal protective
technology related to the four
industries, the information and
technology is relevant and can be
transferred to other industries.
Discussions will highlight the
following four occupational sectors:
1. Agriculture—Discussions will focus
on identifying solutions to major
barriers for appropriate PPE use
practices that occur in pesticide
handling in agricultural crop
production. Discussions will use a
process flow approach for focusing on
each of the critical stages for PPE use in
pesticide handling. Potential barriers
and regulations, such as those identified
from brainstorming meetings of the
NIOSH PPE Surveillance and
Intervention Program for Agricultural
Pesticide Handlers, that may influence
safe performance will be highlighted.
Stakeholders will provide their input,
clarify barriers and help identify
solutions for future development. The
goal of these discussions is to bring
diverse stakeholders together to discuss
barriers to appropriate PPE use and to
jointly formulate and develop creative
solutions.
2. Mining—One session will focus on
technologies to improve current selfcontained self-rescuer (SCSR) designs
and mine rescue ensembles.
Presentations from researchers,
manufacturers, and users will focus on
SCSR design improvements and
technologies to address user needs. The
second session will focus on best
practices learned from ensemble users,
performance requirements for mine
rescue ensembles and identification of
existing limitations and current best
practices.
3. Healthcare—PPE use and usability
issues in acute care and community
healthcare settings and the alignment of
current and recommended PPT research
to narrow knowledge gaps, reduce
exposures, and improve healthcare
worker proper use and compliance will
be emphasized. These sessions will
explore respiratory protective
equipment use and application issues as
well as use and application issues with
other types of PPE commonly used in
healthcare, including integrated
ensembles.
4. Public Safety—These sessions will
focus on personal protective technology
applications, performance/certification
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
standards and use related to the fire
service and law enforcement
communities. Two breakout sessions
will be conducted, one for fire service
and one for law enforcement. The fire
service-related breakout session will
include issues and requirements related
to the design, certification, inspection of
firefighting personal protection
ensembles, and NIOSH research
supporting use of protective ensembles
and respiratory protective equipment by
the fire service. The law enforcement
breakout session will address
performance requirements and
standards for law enforcement
protective ensembles with a focus on
CBRN hazards. The CBRN Protective
Ensemble Standard for Law
Enforcement released by the National
Institute for Justice in late 2010 will be
discussed.
Dated: December 21, 2010.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2010–32964 Filed 12–29–10; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Development of Health Risk
Assessment Guidance; Public Forum
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice of Public Meeting.
On November 16, 2010, the
Centers for Disease Control and
Prevention (CDC), located within the
Department of Health and Human
Services (HHS), published a notice in
the Federal Register (75 FR 70009)
requesting public comment to assist
development of guidance for Health
Risk Assessments (HRAs). Section 4103
of the Affordable Care Act (ACA) (Pub.
L. 111–148) requires that a Health Risk
Assessment be included in the annual
wellness visit benefit authorized for
Medicare beneficiaries under the ACA.
CDC is collaborating with the Centers
for Medicare and Medicaid Services
(CMS), also located within HHS, in the
development of guidance for this type of
assessment. This guidance is also
intended to be useful for HRAs
SUMMARY:
E:\FR\FM\30DEN1.SGM
30DEN1
jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 250 / Thursday, December 30, 2010 / Notices
conducted in other patient populations,
including those persons covered by
employer healthcare plans. In the
November 16, 2010 notice, CDC also
announced that it would hold a public
forum in early February 2011 to obtain
additional public comment. Today’s
notice announces the public forum.
DATES: The public forum will be held
on:
Tuesday, February 1, 2011, from
9 a.m. to 5 p.m. EST and Wednesday,
February 2, 2011, from 9 a.m. to 5 p.m.
EST.
ADDRESSES: The Public Forum will be
held at the Centers for Disease Control
and Prevention, Roybal Campus, Tom
Harkin Global Communications Center,
Building 19, Auditorium A, 1600 Clifton
Road, NE., Atlanta, Georgia 30333.
Upon entering the campus visitors
must stop at the CDC Visitor’s Center
parking guard station. Visitors will be
asked for identification and the purpose
of the visit. Please be aware that your
vehicle is subject to search before being
allowed to enter the facility. A
government-issued photo ID is required
for entry for all adults over the age of
16. Acceptable forms of identification
include a valid driver’s license, a
passport or a state-issued photo
identification card. Parking spaces for
visitors are available in the parking lot
adjacent to the CDC Visitor’s Center
(Building 19). Once inside the CDC
Visitor’s Center, visitors will be asked to
show their picture ID again and a
visitor’s badge will be issued. Those
who have registered in advance will
have a visitor’s badge waiting and entry
will be expedited. Non-U.S. citizens
(including permanent residents) must
register in advance. Please note, this is
a working Federal Facility. Please
follow the guards’ directions.
Backpacks, suitcases or large containers
are prohibited and photography is
restricted.
Please visit our Web site for
additional information on security and
for directions to the facility (https://
www.cdc.gov/museum/security.htm).
CDC will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Paula Staley
at (404) 639–0210 at least 7 days in
advance of the meeting.
Registration: Participants are
encouraged to pre-register for the Public
Forum. On-line registration and a draft
agenda is available at: https://
www.cdc.gov/policy. As space is
limited, registration by January 7, 2011
is strongly encouraged.
VerDate Mar<15>2010
16:35 Dec 29, 2010
Jkt 223001
FOR FURTHER INFORMATION CONTACT:
Paula Staley, Office of Prevention
through Healthcare, Office of the
Associate Director for Policy, Centers for
Disease Control and Prevention, 1600
Clifton Road, NE., Atlanta, Georgia
30333; phone: (404) 639–0210.
Section
4103 of the Affordable Care Act (ACA)
requires that a Health Risk Assessment
(HRA) be included in the annual
wellness visit benefit authorized for
Medicare beneficiaries under the ACA.
CDC is collaborating with the Centers
for Medicare and Medicaid Services
(CMS) in the development of guidance
for this type of assessment. This
guidance is also intended to be useful
for HRAs conducted in other patient
populations such as privately insured
populations, including those persons
covered by employer healthcare plans.
Currently there is considerable variation
in available HRAs, with the majority
created to support employer-based
health and wellness programs. Several
instruments have been created for use in
research and are not available in the
marketplace; and the scientific rigor of
HRA tools is not always evident.
Therefore, the development of HRA
guidance is essential for effective
implementation of this part of the
Medicare wellness visit and to support
broader HRA use within primary care.
Agenda: The meeting will open with
presentations related to background
information on the elderly population,
HRAs and the HRA guidance
development. The meeting will consist
of panel presentations for each of the
areas of emphasis which are listed in
this notice as well as in the November
16, 2010 Federal Register notice.
Participants attending the public forum
will be invited to provide comment at
the end of each half day of the meeting.
The final agenda and panelists’
presentations will be made available to
the public no later than two business
days before the meeting. If CDC is
unable to post the presentations on its
Web site prior to the meeting, the
material will be made publicly available
at the location of the meeting. The final
agenda and panelists’ presentations will
be available at https://www.cdc.gov/
policy. The agenda is subject to change
without notice.
Areas of Emphasis:
SUPPLEMENTARY INFORMATION:
82401
• How should literacy and other
cultural appropriateness factors be
factored into the design?
• Should the HRA instrument
support shared decision-making by
provider and patient? If so, how?
Mode of Administration
• How will individuals access the
HRA (e.g., via kiosk or some other
means in the physician’s office, internet,
mail-in paper form, other nontraditional healthcare locations, such as,
kiosk in a pharmacy)?
• What are the cultural
appropriateness factors in patient HRA
access?
Primary Care Office Capacity
• What primary care office capacity
(personnel, Information Technology
(IT), etc.) is required to utilize HRA data
effectively in support of personalized
prevention planning?
• Is training and technical assistance
necessary for effective practice
utilization of an HRA? What entity
should provide this technical
assistance?
• What are potential or demonstrated
community care transition linkages—
follow-up outside the office by other
providers—that help patients and
providers manage priority risks
identified by the HRA?
• What is the current practice of HRA
in medical practices of various sizes,
particularly those with five or fewer
physicians?
Consumer/Patient Perspective
• How could HRA data be shared
with the patients for their feedback and
follow up in the primary care practice?
• What role, if any, do incentives play
in motivating patients to take the HRA
and/or participate in follow-up
interventions?
Data
• With respect to IT, how could HRA
data entered in any form populate
electronic health records, and what
special challenges and solutions occur if
the data are entered in a non-electronic
form?
• Are there standardized and certified
tools available to support this data
migration from multiple data entry
sources?
Content and Design
Certification
• Risk assessment domains—What
are generic elements of any HRA and
what elements must be tailored to
specific populations, particularly those
stratified by age?
• What certification tools and
processes should complement the HRA
standards and how should they be made
available to support primary care office
selection of an HRA instrument?
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
82402
Federal Register / Vol. 75, No. 250 / Thursday, December 30, 2010 / Notices
jlentini on DSKJ8SOYB1PROD with NOTICES
Evaluation and Quality Assurance
• How should the HRA standards be
evaluated and updated with respect to
individual and population-level
(practice-based panel management)
health outcomes?
Procedure: Interested persons may
present data, information, or views
orally or in writing, on topics listed in
this Federal Register notice. Written
submissions for the public comment
period may be made to the contact
person on or before January 18, 2011.
Oral presentations from the public will
be scheduled during 30-minute public
comment periods at the end of each half
day of proceedings, i.e., from 11:30 a.m.
to 12 noon and 4:30 p.m. to 5 p.m. on
Tuesday, February 1, 2011 and
Wednesday, February 2, 2011. Those
individuals interested in making formal
oral comments should notify the contact
person and submit a brief statement of
the general nature of the comments they
wish to present and the names and
addresses of proposed participants on or
before January 11, 2011. Each
commenter will be limited to 3–5
minutes. The CDC is not responsible for
providing access to electrical outlets.
Individuals who have not submitted
comments ahead of time will have the
opportunity to sign up to comment
during registration on the day of the
forum. However, if time does not allow
for all interested parties to comment,
individuals who have submitted their
comments ahead of time will be given
preference. If the number of participants
requesting to comment is greater than
can be reasonably accommodated, the
CDC may conduct a lottery to determine
the speakers for the scheduled open
public comment sessions. The contact
person will notify interested persons
regarding their request to comment by
January 18, 2011.
Public forum participants not
receiving an opportunity to comment
during the open public comment period
may submit their comments to OPTH
mailbox at: https://www.cdc.gov/policy.
CDC will make all comments it receives
available to the public without change,
including personal information you may
provide, which includes the name of the
person submitting the comment or
signing the comment on behalf of an
organization, business, or any such
entity. If anyone does not wish to have
this information published, then that
information should not be included
when submitting the comment.
VerDate Mar<15>2010
16:35 Dec 29, 2010
Jkt 223001
Dated: December 21, 2010.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2010–32963 Filed 12–29–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Proposed Consolidated Vaccine
Information Materials for Multiple
Infant Vaccines
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
Under the National
Childhood Vaccine Injury Act (NCVIA)
(42 U.S.C. 300aa–26), the CDC must
develop vaccine information materials
that all health care providers are
required to give to patients/parents prior
to administration of specific vaccines.
CDC seeks written comment on a
proposed new vaccine information
statement that consolidates the six
vaccine information statements for the
following childhood vaccines: DTaP,
Haemophilus influenzae type b,
inactivated polio vaccine,
pneumococcal conjugate vaccine,
hepatitis B, and rotavirus. This
consolidated Vaccine Information
Statement is available to be used by
vaccination providers as an alternative
to providing the six individual Vaccine
Information Statements for the same
vaccines.
DATES: Written comments are invited
and must be received on or before
February 28, 2011.
ADDRESSES: Written comments should
be addressed to Jennifer Hamborsky,
National Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention,
Mailstop E–52, 1600 Clifton Road, NE.,
Atlanta, Georgia 30333.
FOR FURTHER INFORMATION CONTACT: Skip
Wolfe, National Center for
Immunization and Respiratory Diseases,
Mailstop E–52, 1600 Clifton Road, NE.,
Atlanta, Georgia 30333, telephone (404)
639–8809.
SUPPLEMENTARY INFORMATION: The
National Childhood Vaccine Injury Act
of 1986 (Pub. L. 99–660), as amended by
section 708 of Public Law 103–183,
added section 2126 to the Public Health
Service Act. Section 2126, codified at 42
U.S.C. 300aa–26, requires the Secretary
of Health and Human Services to
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
develop and disseminate vaccine
information materials for distribution by
all health care providers in the United
States to any patient (or to the parent or
legal representative in the case of a
child) receiving vaccines covered under
the National Vaccine Injury
Compensation Program.
Development and revision of the
vaccine information materials, also
known as Vaccine Information
Statements (VIS), have been delegated
by the Secretary to the Centers for
Disease Control and Prevention (CDC).
Section 2126 requires that the materials
be developed, or revised, after notice to
the public, with a 60-day comment
period, and in consultation with the
Advisory Commission on Childhood
Vaccines, appropriate health care
provider and parent organizations, and
the Food and Drug Administration. The
law also requires that the information
contained in the materials be based on
available data and information, be
presented in understandable terms, and
include:
(1) A concise description of the
benefits of the vaccine,
(2) A concise description of the risks
associated with the vaccine,
(3) A statement of the availability of
the National Vaccine Injury
Compensation Program, and
(4) Such other relevant information as
may be determined by the Secretary.
The vaccines initially covered under
the National Vaccine Injury
Compensation Program were diphtheria,
tetanus, pertussis, measles, mumps,
rubella and poliomyelitis vaccines.
Since April 15, 1992, any health care
provider in the United States who
intends to administer one of these
covered vaccines is required to provide
copies of the relevant vaccine
information materials prior to
administration of any of these vaccines.
Hepatitis B, Haemophilus influenzae
type b (Hib), varicella (chickenpox),
pneumococcal conjugate, hepatitis A,
meningococcal conjugate and
polysaccharide, rotavirus, human
papillomavirus (HPV), and trivalent
influenza vaccines have subsequently
been added to the National Vaccine
Injury Compensation Program. Use of
the Vaccine Information Statements
applicable to all of these vaccines,
except meningococcal, rotavirus and
HPV, is also required. (Interim versions
of Vaccine Information Statements for
meningococcal, rotavirus and HPV
vaccines are available for discretionary
use pending completion of the statutory
process for finalizing VISs applicable to
those vaccines.) Instructions for use of
the vaccine information materials and
copies of the materials can be found on
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 75, Number 250 (Thursday, December 30, 2010)]
[Notices]
[Pages 82400-82402]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32963]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Development of Health Risk Assessment Guidance; Public Forum
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of Public Meeting.
-----------------------------------------------------------------------
SUMMARY: On November 16, 2010, the Centers for Disease Control and
Prevention (CDC), located within the Department of Health and Human
Services (HHS), published a notice in the Federal Register (75 FR
70009) requesting public comment to assist development of guidance for
Health Risk Assessments (HRAs). Section 4103 of the Affordable Care Act
(ACA) (Pub. L. 111-148) requires that a Health Risk Assessment be
included in the annual wellness visit benefit authorized for Medicare
beneficiaries under the ACA. CDC is collaborating with the Centers for
Medicare and Medicaid Services (CMS), also located within HHS, in the
development of guidance for this type of assessment. This guidance is
also intended to be useful for HRAs
[[Page 82401]]
conducted in other patient populations, including those persons covered
by employer healthcare plans. In the November 16, 2010 notice, CDC also
announced that it would hold a public forum in early February 2011 to
obtain additional public comment. Today's notice announces the public
forum.
DATES: The public forum will be held on:
Tuesday, February 1, 2011, from 9 a.m. to 5 p.m. EST and Wednesday,
February 2, 2011, from 9 a.m. to 5 p.m. EST.
ADDRESSES: The Public Forum will be held at the Centers for Disease
Control and Prevention, Roybal Campus, Tom Harkin Global Communications
Center, Building 19, Auditorium A, 1600 Clifton Road, NE., Atlanta,
Georgia 30333.
Upon entering the campus visitors must stop at the CDC Visitor's
Center parking guard station. Visitors will be asked for identification
and the purpose of the visit. Please be aware that your vehicle is
subject to search before being allowed to enter the facility. A
government-issued photo ID is required for entry for all adults over
the age of 16. Acceptable forms of identification include a valid
driver's license, a passport or a state-issued photo identification
card. Parking spaces for visitors are available in the parking lot
adjacent to the CDC Visitor's Center (Building 19). Once inside the CDC
Visitor's Center, visitors will be asked to show their picture ID again
and a visitor's badge will be issued. Those who have registered in
advance will have a visitor's badge waiting and entry will be
expedited. Non-U.S. citizens (including permanent residents) must
register in advance. Please note, this is a working Federal Facility.
Please follow the guards' directions. Backpacks, suitcases or large
containers are prohibited and photography is restricted.
Please visit our Web site for additional information on security
and for directions to the facility (https://www.cdc.gov/museum/security.htm).
CDC will make every effort to accommodate persons with physical
disabilities or special needs. If you require special accommodations
due to a disability, please contact Paula Staley at (404) 639-0210 at
least 7 days in advance of the meeting.
Registration: Participants are encouraged to pre-register for the
Public Forum. On-line registration and a draft agenda is available at:
https://www.cdc.gov/policy. As space is limited, registration by January
7, 2011 is strongly encouraged.
FOR FURTHER INFORMATION CONTACT: Paula Staley, Office of Prevention
through Healthcare, Office of the Associate Director for Policy,
Centers for Disease Control and Prevention, 1600 Clifton Road, NE.,
Atlanta, Georgia 30333; phone: (404) 639-0210.
SUPPLEMENTARY INFORMATION: Section 4103 of the Affordable Care Act
(ACA) requires that a Health Risk Assessment (HRA) be included in the
annual wellness visit benefit authorized for Medicare beneficiaries
under the ACA. CDC is collaborating with the Centers for Medicare and
Medicaid Services (CMS) in the development of guidance for this type of
assessment. This guidance is also intended to be useful for HRAs
conducted in other patient populations such as privately insured
populations, including those persons covered by employer healthcare
plans. Currently there is considerable variation in available HRAs,
with the majority created to support employer-based health and wellness
programs. Several instruments have been created for use in research and
are not available in the marketplace; and the scientific rigor of HRA
tools is not always evident. Therefore, the development of HRA guidance
is essential for effective implementation of this part of the Medicare
wellness visit and to support broader HRA use within primary care.
Agenda: The meeting will open with presentations related to
background information on the elderly population, HRAs and the HRA
guidance development. The meeting will consist of panel presentations
for each of the areas of emphasis which are listed in this notice as
well as in the November 16, 2010 Federal Register notice. Participants
attending the public forum will be invited to provide comment at the
end of each half day of the meeting. The final agenda and panelists'
presentations will be made available to the public no later than two
business days before the meeting. If CDC is unable to post the
presentations on its Web site prior to the meeting, the material will
be made publicly available at the location of the meeting. The final
agenda and panelists' presentations will be available at https://www.cdc.gov/policy. The agenda is subject to change without notice.
Areas of Emphasis:
Content and Design
Risk assessment domains--What are generic elements of any
HRA and what elements must be tailored to specific populations,
particularly those stratified by age?
How should literacy and other cultural appropriateness
factors be factored into the design?
Should the HRA instrument support shared decision-making
by provider and patient? If so, how?
Mode of Administration
How will individuals access the HRA (e.g., via kiosk or
some other means in the physician's office, internet, mail-in paper
form, other non-traditional healthcare locations, such as, kiosk in a
pharmacy)?
What are the cultural appropriateness factors in patient
HRA access?
Primary Care Office Capacity
What primary care office capacity (personnel, Information
Technology (IT), etc.) is required to utilize HRA data effectively in
support of personalized prevention planning?
Is training and technical assistance necessary for
effective practice utilization of an HRA? What entity should provide
this technical assistance?
What are potential or demonstrated community care
transition linkages--follow-up outside the office by other providers--
that help patients and providers manage priority risks identified by
the HRA?
What is the current practice of HRA in medical practices
of various sizes, particularly those with five or fewer physicians?
Consumer/Patient Perspective
How could HRA data be shared with the patients for their
feedback and follow up in the primary care practice?
What role, if any, do incentives play in motivating
patients to take the HRA and/or participate in follow-up interventions?
Data
With respect to IT, how could HRA data entered in any form
populate electronic health records, and what special challenges and
solutions occur if the data are entered in a non-electronic form?
Are there standardized and certified tools available to
support this data migration from multiple data entry sources?
Certification
What certification tools and processes should complement
the HRA standards and how should they be made available to support
primary care office selection of an HRA instrument?
[[Page 82402]]
Evaluation and Quality Assurance
How should the HRA standards be evaluated and updated with
respect to individual and population-level (practice-based panel
management) health outcomes?
Procedure: Interested persons may present data, information, or
views orally or in writing, on topics listed in this Federal Register
notice. Written submissions for the public comment period may be made
to the contact person on or before January 18, 2011. Oral presentations
from the public will be scheduled during 30-minute public comment
periods at the end of each half day of proceedings, i.e., from 11:30
a.m. to 12 noon and 4:30 p.m. to 5 p.m. on Tuesday, February 1, 2011
and Wednesday, February 2, 2011. Those individuals interested in making
formal oral comments should notify the contact person and submit a
brief statement of the general nature of the comments they wish to
present and the names and addresses of proposed participants on or
before January 11, 2011. Each commenter will be limited to 3-5 minutes.
The CDC is not responsible for providing access to electrical outlets.
Individuals who have not submitted comments ahead of time will have
the opportunity to sign up to comment during registration on the day of
the forum. However, if time does not allow for all interested parties
to comment, individuals who have submitted their comments ahead of time
will be given preference. If the number of participants requesting to
comment is greater than can be reasonably accommodated, the CDC may
conduct a lottery to determine the speakers for the scheduled open
public comment sessions. The contact person will notify interested
persons regarding their request to comment by January 18, 2011.
Public forum participants not receiving an opportunity to comment
during the open public comment period may submit their comments to OPTH
mailbox at: https://www.cdc.gov/policy. CDC will make all comments it
receives available to the public without change, including personal
information you may provide, which includes the name of the person
submitting the comment or signing the comment on behalf of an
organization, business, or any such entity. If anyone does not wish to
have this information published, then that information should not be
included when submitting the comment.
Dated: December 21, 2010.
Tanja Popovic,
Deputy Associate Director for Science, Centers for Disease Control and
Prevention.
[FR Doc. 2010-32963 Filed 12-29-10; 8:45 am]
BILLING CODE 4163-18-P
